Abstract
ObjectiveThe purpose of the present study was to detect novel glycolysis-related gene signatures of prognostic values for patients with clear cell renal cell carcinoma (ccRCC).MethodsGlycolysis-related gene sets were acquired from the Molecular Signatures Database (V7.0). Gene Set Enrichment Analysis (GSEA) software (4.0.3) was applied to analyze glycolysis-related gene sets. The Perl programming language (5.32.0) was used to extract glycolysis-related genes and clinical information of patients with ccRCC. The receiver operating characteristic curve (ROC) and Kaplan–Meier curve were drawn by the R programming language (3.6.3).ResultsThe four glycolysis-related genes (B3GAT3, CENPA, AGL, and ALDH3A2) associated with prognosis were identified using Cox proportional regression analysis. A risk score staging system was established to predict the outcomes of patients with ccRCC. The patients with ccRCC were classified into the low-risk group and high-risk group.ConclusionsWe have successfully constructed a risk staging model for ccRCC. The model has a better performance in predicting the prognosis of patients, which may have positive reference value for the treatment and curative effect evaluation of ccRCC.
Highlights
Renal cell carcinoma (RCC) is one of the most common malignant tumors of the urinary system (Ferlay et al, 2010)
The mRNA expression profiles were from 72 paracancerous samples and 539 patients with Clear cell renal cell carcinoma (ccRCC)
Gene set enrichment analysis (GSEA) was used for the transcriptome data to explore whether the glycolysis-related gene sets showed statistical differences between the ccRCC and adjacent normal tissues
Summary
Renal cell carcinoma (RCC) is one of the most common malignant tumors of the urinary system (Ferlay et al, 2010). Clear cell renal cell carcinoma (ccRCC) is the predominant RCC subtype, occupying 75% (Fan et al, 2015). Insidious onset of ccRCC and lack of specific symptoms and effective diagnostic and therapeutic tools result in an advanced stage and poor prognosis when diagnosed (Jonasch et al, 2014). Molecular targeted therapy for advanced or metastatic ccRCC has notable curative effectiveness. There is still a lack of effective molecular markers to evaluate the prognosis of patients with ccRCC and Glycolysis-Related Prognosis Gene of ccRCC the effects of targeted drug therapy. Inhibition of glycolysis has the effect of inhibiting proliferation and killing tumor cells. It is of great significance to screen glycolysis-related genes associated with the prognosis of patients with ccRCC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
